Menu
1 min read · estimated
APPROVED USE
What FDA approved
For adults with relapsed or refractory AML with a susceptible NPM1 mutation and no satisfactory alternative treatment options.
LAMPGEN ANALYSIS
Why it matters
This menin inhibitor adds an adult option in relapsed or refractory NPM1-mutated AML.
What research teams should watch
Document actionable NPM1 status and establish a site escalation plan for suspected differentiation syndrome.
PRIMARY RECORDS